Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

iRhom2 in AD

Financiado

Cerrado

iRhom2 in neuroinflammation and pathogenesis of Alzheimer s Disease

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, a syndrome characterized by loss of memory and cognitive decline. AD has a dramatic socio-economical impact that is foreseen to worsen in the near future... ver más

30/11/2017

TUM-MED

159K€

Presupuesto del proyecto: 159K€

Líder del proyecto

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIV... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-11-30

MSCA-IF-2014-EF: Marie Skłodowska-Curie Individual F...

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TUM-MED

159.46K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IMMUNOALZHEIMER The role of immune cells in Alzheimer s disease 3M€ Cerrado

PID2019-111240RA-I00 ALTERACIONES DE LA ENFERMEDAD DE ALZHEIMER CAUSADAS POR LA A... 155K€ Cerrado

SAF2016-80419-R REGULACION DE LA MULTIPOTENCIALIDAD DE CELULAS MADRE NEURALE... 157K€ Cerrado

PID2020-119236RB-I00 ESTUDIO DE LA FUNCION TRANSNEURONAL DE LA PROTEINA RTP801/RE... 206K€ Cerrado

SAF2013-42445-R NUEVAS APROXIMACIONES A LA PATOGENESIS DE LA ENFERMEDAD DE A... 496K€ Cerrado

HUMANE Window to the brain: a game changer in the discovery of huma... 2M€ Cerrado

Duración del proyecto: 31 meses Fecha Inicio: 2015-04-22
Fecha Fin: 2017-11-30

Líder del proyecto

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIV... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 159K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Alzheimer’s disease (AD) is the most common form of dementia in the elderly, a syndrome characterized by loss of memory and cognitive decline. AD has a dramatic socio-economical impact that is foreseen to worsen in the near future unless a cure is found. The pathology is triggered by the accumulation of Aβ oligomers that begins a cascade culminating with the formation of neurofibrillary tangles within the neuron and cell death. Neuroinflammation is emerging to play a key role in this process and it has been associated with the progression of the disease. The rhomboid-like protein iRhom2 has been recently identified as a genetic risk factor for AD, even though the underlying mechanism remains to be characterized. iRhom2 recently emerged as a novel pro-inflammatory protein required to traffic TACE (tumor necrosis factor-α converting enzyme) towards the plasma membrane and guide its maturation, thereby regulating the release of TNFα, a cytokine implicated in several inflammatory diseases. Consequently, iRhom2-/- mice are protected from sepsis and rheumatoid arthritis, which involve TNFα-dependent inflammation. In addition, the concept is emerging that iRhom2 may regulate trafficking of additional clients other than TACE, thus controlling other signalling events in neuroinflammation. The main objective of this proposal is to characterize the role of iRhom2 in neuroinflammation and in the progression of AD. I plan to cross an AD mouse model with iRhom2-/- mice and evaluate role of iRhom2 in the progression of the disease. In addition, I will use avant-garde proteomic approaches to identify novel iRhom2 clients in primary macrophages. Candidates relevant in neuroinflammation and AD will be further validated using an array of biochemical and functional assays. From this research I aim to identify new targets to develop therapies for treatment of AD, in line with the objectives of H2020 Work Programme to promote healthy ageing of the EU citizens.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores